These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 36227615)
1. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. Miao J; Wang L; Tan SH; Li JG; Yi J; Ong EHW; Tan LLY; Zhang Y; Gong X; Chen Q; Xiang YQ; Chen MY; Guo Y; Lv X; Xia WX; Tang L; Deng X; Guo X; Han F; Mai HQ; Chua MLK; Zhao C JAMA Oncol; 2022 Oct; 8(12):1776-85. PubMed ID: 36227615 [TBL] [Abstract][Full Text] [Related]
2. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. Li WZ; Lv X; Hu D; Lv SH; Liu GY; Liang H; Ye YF; Yang W; Zhang HX; Yuan TZ; Wang DS; Lu N; Ke LR; Tang WB; Tong LH; Chen ZJ; Liu T; Cao KJ; Mo HY; Guo L; Zhao C; Chen MY; Chen QY; Huang PY; Sun R; Qiu F; Luo DH; Wang L; Hua YJ; Tang LQ; Qian CN; Mai HQ; Guo X; Xiang YQ; Xia WX JAMA Oncol; 2022 May; 8(5):706-714. PubMed ID: 35323856 [TBL] [Abstract][Full Text] [Related]
3. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416 [TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411 [TBL] [Abstract][Full Text] [Related]
5. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial. Tang QN; Liu LT; Qi B; Guo SS; Luo DH; Sun R; Sun XS; Chen DP; Guo L; Mo HY; Wang P; Liu SL; Liang YJ; Li XY; Yang ZC; Chen QY; Mai HQ; Tang LQ JAMA Netw Open; 2021 Dec; 4(12):e2138470. PubMed ID: 34928359 [TBL] [Abstract][Full Text] [Related]
6. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial. Liu GY; Li WZ; Wang DS; Liang H; Lv X; Ye YF; Zhao C; Ke LR; Lv SH; Lu N; Bei WX; Cai ZC; Chen X; Liang CX; Guo X; Xia WX; Xiang YQ JAMA Oncol; 2022 Apr; 8(4):553-561. PubMed ID: 35175316 [TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Liu LT; Liu H; Huang Y; Yang JH; Xie SY; Li YY; Guo SS; Qi B; Li XY; Chen DP; Jin F; Sun XS; Yang ZC; Liu SL; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Qiu F; Yang Q; Liang YJ; Jia GD; Wen DX; Yan JJ; Zhao C; Chen QY; Sun R; Tang LQ; Mai HQ Lancet Oncol; 2023 Jul; 24(7):798-810. PubMed ID: 37290468 [TBL] [Abstract][Full Text] [Related]
8. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591 [TBL] [Abstract][Full Text] [Related]
9. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant Gemcitabine Plus Cisplatin and Chemoradiation in Patients With Gallbladder Cancer: A Randomized Clinical Trial. Ostwal V; Patkar S; Engineer R; Parulekar M; Mandavkar S; Bhargava P; Srinivas S; Krishnatry R; Gudi S; Kapoor A; Pandey D; Patel S; Singhal A; Goel A; Dora TK; Chaudhary D; Chaugule D; Naughane D; Daddi A; Patil R; Ankathi SK; Ramaswamy A; Goel M JAMA Oncol; 2024 Aug; 10(8):1116-1120. PubMed ID: 38958997 [TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J Eur J Cancer; 2017 Apr; 75():150-158. PubMed ID: 28235726 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653 [TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945 [TBL] [Abstract][Full Text] [Related]
15. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Lee AW; Ngan RK; Tung SY; Cheng A; Kwong DL; Lu TX; Chan AT; Chan LL; Yiu H; Ng WT; Wong F; Yuen KT; Yau S; Cheung FY; Chan OS; Choi H; Chappell R Cancer; 2015 Apr; 121(8):1328-38. PubMed ID: 25529384 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Setakornnukul J; Thephamongkhol K BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665 [TBL] [Abstract][Full Text] [Related]
17. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391 [TBL] [Abstract][Full Text] [Related]
18. The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial. Luo Y; Cai B; Li B; Liu F; Du L; Zhao D; Fan W; Meng L; Zhang X; Ma L Technol Cancer Res Treat; 2022; 21():15330338221109974. PubMed ID: 35770295 [No Abstract] [Full Text] [Related]
19. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
20. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]